Matthew E. Hyndman

Urology

600 N Wolfe St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models.

Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models.

Journal: NPJ digital medicine

Published: April 24, 2025

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform.

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform.

Journal: NPJ digital medicine

Published: March 08, 2024

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.

Journal: European urology open science

Published: May 24, 2022

The association of bladder cancer and Cannabis: A systematic review.

The association of bladder cancer and Cannabis: A systematic review.

Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Published: March 18, 2022

Evaluation of the Implementation of Multiple Enhanced Recovery After Surgery Pathways Across a Provincial Health Care System in Alberta, Canada.

Evaluation of the Implementation of Multiple Enhanced Recovery After Surgery Pathways Across a Provincial Health Care System in Alberta, Canada.

Journal: JAMA network open

Published: August 06, 2021

Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.

Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.

Journal: Molecular & cellular proteomics : MCP

Published: February 23, 2021

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.

Journal: Urologic oncology

Published: February 17, 2021

A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy.

A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy.

Journal: BJUI compass

Published: October 18, 2020

Tissue-selective alternate promoters guide NLRP6 expression.

Tissue-selective alternate promoters guide NLRP6 expression.

Journal: Life science alliance

Published: August 28, 2020

Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.

Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.

Journal: The Prostate

Published: March 04, 2020

Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin.

Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin.

Journal: Biochimica et biophysica acta. Biomembranes

Published: December 24, 2019

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Journal: The Journal of urology

Published: December 11, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026